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ABSTRACT
Large synthetic genetic circuits require the simulta-
neous expression of many regulators. Deactivated
Cas9 (dCas9) can serve as a repressor by having a
small guide RNA (sgRNA) direct it to bind a promoter.
The programmability and specificity of RNA:DNA
basepairing simplifies the generation of many or-
thogonal sgRNAs that, in theory, could serve as a
large set of regulators in a circuit. However, dCas9 is
toxic in many bacteria, thus limiting how high it can
be expressed, and low concentrations are quickly se-
questered by multiple sgRNAs. Here, we construct a
non-toxic version of dCas9 by eliminating PAM (pro-
tospacer adjacent motif) binding with a R1335K mu-
tation (dCas9*) and recovering DNA binding by fus-
ing it to the PhlF repressor (dCas9* PhlF). Both the
30 bp PhlF operator and 20 bp sgRNA binding site
are required to repress a promoter. The larger re-
gion required for recognition mitigates toxicity in Es-
cherichia coli, allowing up to 9600 ± 800 molecules
of dCas9* PhlF per cell before growth or morphology
are impacted, as compared to 530 ± 40 molecules of
dCas9. Further, PhlF multimerization leads to an in-
crease in average cooperativity from n = 0.9 (dCas9)
to 1.6 (dCas9* PhlF). A set of 30 orthogonal sgRNA–
promoter pairs are characterized as NOT gates; how-
ever, the simultaneous use of multiple sgRNAs leads
to a monotonic decline in repression and after 15
are co-expressed the dynamic range is<10-fold. This
work introduces a non-toxic variant of dCas9, critical
for its use in applications in metabolic engineering
and synthetic biology, and exposes a limitation in
the number of regulators that can be used in one cell
when they rely on a shared resource.
INTRODUCTION
Synthetic regulatory networks enable the control of when
genes are turned on (1). Natural networks can consist of
hundreds of regulators, but implementing synthetic ver-
sions at this scale has proven elusive (2). Regulators used to
build such networks have to perform reliably, cannot inter-
fere with each other, and minimally tax cellular resources
(3). Sets of protein-based repressors and activators have
been used to build regulatory circuits, but expanding the
set becomes increasingly difficult as each new protein needs
to be tested for cross-reactions with the remainder in the
set (4–8). Further, protein expression draws on cellular re-
sources (ATP, ribosomes, amino acids, etc.), and this can
result in slow growth, reduced metabolic performance, and
evolutionary instability (9–11).
Regulators based on CRISPR (clustered regularly inter-
spaced short palindromic repeats) machinery offer a poten-
tial solution (12–17). Catalytically inactive dCas9 can be
used as a repressor by using the small guide RNA (sgRNA)
to target a sequence within a promoter to sterically block
RNA polymerase (RNAP) (18,19). The target sequence in
the promoter is based on a 3 nt PAM sequence, which binds
to the dCas9 protein, and a 20 nt targeting region that base-
pairs with the sgRNA.DifferentDNA sequences can be tar-
geted by changing this region, which has been the basis for
building large sets of sgRNA–promoter pairs that exhibit
little or no crosstalk. Up to five pairs have been shown in
Escherichia coli (20) and up to 20 pairs in yeast (21), but
theoretically thousands could be made, essentially solving
the need for orthogonal regulators to build large networks.
In addition, sgRNA-circuits do not require translation to
function, thus simplifying their use in the nucleus of eu-
karyotic cells. Previously, dCas9 has been used to build sim-
ple logic circuits and cascades with up to three sgRNAs in
bacteria, seven sgRNAs in yeast and four sgRNAs in mam-
malian cells (20–26).
Despite the promise, there are several limitations in the
scale-up of dCas9-based circuits. The foremost challenge is
that high concentrations of dCas9 is toxic in many bacte-
ria (27–29). This can be avoided for genome editing and
CRISPR interference (CRISPRi) experiments by keeping
the concentration low or limiting how long it is expressed
(30). However, for a genetic circuit, dCas9 needs to be con-
tinuously available, including under the conditions required
by the application, for example in a fermenter. This is com-
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pounded by the problem that multiple sgRNAs all have to
share the same pool of dCas9. The draw-down of a shared
resource leads to changes in performance of all the sgRNA,
referred to as ‘retroactivity,’ and this can have a damaging
impact on circuit function (31–34). Further, sgRNA-based
gates have remarkably low cooperativity (Hill coefficient n
≈ 1.0) (20). Higher cooperativities are required to build reg-
ulation that implement multistable switches, feedback con-
trol, cascades, and oscillations (n> 1) (35–38). In yeast, the
cooperativity of sgRNA-based regulation was increased by
fusing dCas9 to the chromatin remodeling repression do-
mainMxi1, but there is no equivalent approach for prokary-
otes (21).
The origins of dCas9 toxicity are poorly understood.
It has been observed that dCas9 binds non-specifically to
NGG PAM sites, particularly when unbound to a sgRNA,
and there are many GG sequences in the genome (5.4 ×
105 PAM sites per E. coli genome) (39). While it primar-
ily binds to this motif, it has been shown that it can also
inefficiently recognize other PAM (e.g. NAG or NGA) se-
quences (40,41). Further, dCas9 functions by first actively
interrogating the genome to search for the PAM motif,
and then checking the complementarity of the sgRNA se-
quence to the target site (14,18). The search for PAM bind-
ing involves actively opening the DNA double strands in
the chromosome (42). Previous studies also demonstrated
that off-target genomic loci with up to six nucleotides that
differ from the sgRNA sequence could still be recognized
by Cas9, albeit with lower efficiency (but still requiring the
PAM site) (43). These observations collectively point to the
non-specific binding to NGG sequences by dCas9 as being
a significant contributor to toxicity.
We hypothesized that reducing the non-specific binding
of dCas9 would alleviate toxicity. The specificity of active
Cas9 for genome editing applications has been increased via
a variety of strategies, including point mutations to enhance
PAM binding (44,45), increasing sgRNA length (46,47),
splitting Cas9 (48–50), and the use of a pair of Cas9 nick-
ases or FokI-dCas9 nucleases to increase the length of tar-
geting sequence (51,52). It has been shown that Cas9 can
be mutated (R1335K) to impair its ability to recognize the
PAM, thus completely blocking DNA cleavage (53). Cleav-
age could be partially rescued by fusing aDNAbinding pro-
tein (a ZFP or TALE) to dCas9 and placing the correspond-
ing operator upstream of the region targeted by the sgRNA.
The longer effective ‘operator’ increase cleavages specificity.
Here, we apply this strategy to dCas9, but find that a fusion
to the TetR-family PhlF repressor is uniquely able to re-
cover full activity.We find this essentially eliminates toxicity,
thus allowing up to 9600 proteins per cell without impairing
cell health. Promoters are constructed that include the 30
bp PhlF operator and the sgRNA targeting sequence. A set
of 30 sgRNAs are constructed and characterized as NOT
gates with improved cooperativity (<n> = 1.6). Finally, we
quantify the loss in dynamic range of a gate as additional
sgRNAs are expressed and a mathematical model is used to
quantify the loss in repression due to resource sharing. This
work represents the first step towards harnessing dCas9 to
scale-up circuit design; however, it also exposes limitations
in the use of many regulators that require a shared pool of
proteins for activity.
MATERIALS AND METHODS
Strains and media
All cloning was performed in E. coli NEB 10-beta (New
England Biolabs, #C3019) and cells were grown in LB
Miller broth (Difco, MI, #90003-350). The measurements
experiments were done in E. coli K-12 MG1655 * [F-
- ilvG- rfb-50 rph-1 (araCBAD) (LacI)] (20,54), and
MOPS EZ Rich Defined Medium was used (Teknova,
#M2105) with 0.2% glucose (Thermo Fisher Scientific,
#156129) as carbon source for cell growth. Ampicillin
(100 g/ml, GoldBio, #A-301-5), kanamycin (50 g/ml,
GoldBio, #K-120-5), and spectinomycin sulfate (50 g/ml,
GoldBio, #S-140-5) were used to maintain plasmids when
appropriate.
Induction assays
Individual colonies were inoculated into 150 l MOPS EZ
Rich Defined Medium with appropriate antibiotics and
then grown overnight (∼16 h) in 96-well plates (Nunc,
Roskilde, Denmark, #249952) at 1000 rpm and 37◦C on a
plate shaker (ELMI, #DTS-4). Cultures were diluted 1000-
fold by adding 2 l of culture to 198 l media, and then
15 l of that dilution to 135 l media, and grown with the
same shaking condition for 3 h. At this point, cells were di-
luted 3000-fold by adding 2 l of culture to 198 l media,
and then 5 l of that dilution to 145 l media with inducers
and antibiotics as needed, and then were grown under the
same conditions for 6 h.
Flow cytometry analyses
Aliquots of 40 l of media containing cells were col-
lected and added to 160 l phosphate-buffered saline with
1 mg/ml kanamycin to stop translation and arrest cell
growth. The LSRII Fortessa flow cytometer (BD Bio-
sciences, San Jose, CA, USA) was used to quantify the
fluorescent protein production. The software FlowJo v10
(TreeStar, Inc., Ashland, OR) was used to gate the events
by forward and side scatter, and at least 10 000 events were
collected for each sample. The geometric mean of each sam-
ple was calculated. The autofluorescence of white cells was
subtracted, defined as the geometric mean of a strain har-
boring an empty backbone (pSZ Backbone, Supplemen-
tary Figure S12) grown under identical conditions. The
fold-repression is measured as the uninduced divided by
the induced fluorescence values. In Supplementary Figure
S9, ±sgRNA fold-change indicates the repression of a pro-
moter in the presence and absence of a plasmid from which
the sgRNA is expressed. To calculate this, the fluorescence
is measured for both strains and the ratio reported.
Growth assay
Individual colonies were inoculated into 150 l MOPS EZ
Rich Defined Medium with appropriate antibiotics and
then grown overnight (∼16 h) in 96-well plates (Nunc,
Roskilde, Denmark, #249952) at 1000 rpm and 37◦C on a
plate shaker (ELMI, #DTS-4). Cultures were diluted 1000-
fold by adding 2 l of culture to 198 l media, and then
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15 l of that dilution to 135 l media, and grown with the
same shaking condition for 3 h. After the 3 h step, the cul-
tures were diluted 3000-fold by adding 2l of culture to 198
l media, and then 5 l of that dilution to 145 l media
with appropriate antibiotics and different inducers concen-
trations. The dilutions were made in 96-well plates (Nunc,
Roskilde, Denmark, #165305) and grown at 1000 rpm and
37◦C for 6 h. The optical density at 600 nm was measured
on a SynergyH1 plate reader (BioTek,Winooski, VT,USA)
and the background of MOPS EZ Rich Defined Medium
was subtracted. The measured values were then normalized
to the un-induced samples (0 ng/ml aTc).
Microscopy
During the growth assay, after 6 hours, aliquots (2l) of cul-
tures were collected. Microscopic images of these cultures
were then taken on the Axiovert 200m microscope (Carl
Zeiss, Oberkochen, Germany).
Numbers of cells per ml
Colonies were inoculated into 150 l MOPS EZ Rich De-
fined Medium with appropriate antibiotics and then grown
overnight (∼16 h). The next day, these cultures were diluted
by adding 1 l culture into 1 ml fresh media. After 5 h of
growth (1000 rpm and 37◦C), the culture density was mea-
sured and diluted to different OD600nm. The cultures at dif-
ferent OD600nm were then diluted 2× 107-fold and plated on
LB agar. Colony numbers were then counted after overnight
growth at 37◦C.
Quantification of dCas9
Colonies were inoculated into 150 l MOPS EZ Rich De-
fined Medium with appropriate antibiotics and then grown
overnight (∼16 h). The next day, these cultures were diluted
by adding 1 l culture into 1 ml fresh media containing in-
ducer (2.5 ng/ml or 0.7 ng/ml aTc). After 5 h of growth
(1000 rpm and 37◦C), the culture density was measured
and adjusted to OD600nm = 1 with MOPS EZ Rich De-
finedMedium. 700 l of the adjusted culture for each strain
was centrifuged at 12 000 rpm for 1 min. The supernatant
was discarded and cell pellet was re-suspended in 40 l lysis
buffer (100mMNaCl, 25mMTris–HCl, pH8.0) containing
0.2 % -mercaptoethanol (Sigma-Aldrich, #M6250). The
samples were boiled at 100◦C for 5 min, after which 3 l of
the dCas9 sample and 0.75 l of the dCas9* PhlF sample
were added to lysis buffer to a final volume of 20 l.
To prepare the standard curve, 2 l of purchased Cas9
complex (New England Biolabs, #M0386S) was added to
38 l lysis buffer. Then, different amounts (0.2, 1, 3, 5 l) of
the diluted Cas9 standard, 3 l WT lysate, and lysis buffer
were added to each sample to a total volume of 20 l.
The same amount (10 l) of the resulting standards and
cell lysates were loaded on a 4–12 % gradient SDS-PAGE
gel (Lonza, # 59524). After the run, the gels were trans-
ferred onto a PVDF membrane (Biorad, #162-0177) and
then blocked at room temperature for 1 h in 5% skim milk
(w/v of TBST, 138 mMNaCl, 2.7 mMKCl, 0.1% Triton X-
100, 25mMTris–HCl, pH 8.0). The anti-Cas9 antibody (ab-
cam, #ab202580) was used as primary antibody and added
1:2000 into 2.5% skim milk (w/v of TBST). The primary
antibody solution was then added to the PVDF membrane
and allowed to bind for 1 hour at room temperature. The
membrane was then washed three times with TBST. The
secondary antibody, HRP-conjugated anti-mouse antibody
(Sigma, #A8924), was added to 1:4000 and incubated for
1 h at room temperature. After washing the membrane,
chemiluminescence for HRP (Pierce, #32106) was used to
develop the signal and detected using the Biorad chemi-
doc MP imaging system (Biorad, #170-8280). ImageJ 1.41
(NIH) was used to analyze the gel densitometry. The rela-
tive protein numbers of dCas9 in the strain was calculated
from the standard curve and known concentrations of Cas9
standards (Supplementary Figure S3).
Random sequence generation
The random sequences are generated using the online Ran-
dom DNA Sequence Generator (http://www.faculty.ucr.
edu/~mmaduro/random.htm) with GC content set to 50%.
sgRNA array
Pairs of ssDNA oligonucleotides ≤200 nt long that en-
code the necessary genetic parts (promoter, sgRNA, ter-
minator) were ordered from Integrated DNA Technologies
(IDT). These oligos are annealed by PCRusingKAPAHiFi
MasterMix (KAPA Biosystems, #07958935001) and the re-
sulting dsDNA modules were then assembled in a one-pot
Golden Gate assembly reaction using type II enzymes BsaI
(New England Biolabs, #R0535S) or BsmbI (New Eng-
land Biolabs, #R0580S) to generate plasmids with differ-
ent numbers of sgRNAs. After transformation, these plas-
mids were re-purified and digested with restriction enzyme
BsphI (New England Biolabs, #R0517S) to make sure they
have the expected sizes and thus rule out the possibility of
unwanted homologous recombination during construction
and transformation (Supplementary Figure S8).
Energy cost of expressing dCas9* PhlF and TetR
The following is an estimation of the number of ATPs re-
quired to synthesize aTetR repressor and dCas9* PhlF. The
tetR gene is 624 bp and the TetR protein contains 207 amino
acids. The cost of mRNA has been estimated to be 6 ATP
per triplet (55), making the total cost of the tetR mRNA to
be approximately 1242 ATP. On average one mRNA pro-
duces 30 proteins, thus the cost per protein is 41 ATP (55).
Using Table 1 from ref. (55), the cost of making the amino
acids for TetR is -307 ATP (negative indicating a net in-
crease of ATP). Translation costs 4 ATP/amino acid. Tak-
ing all of these factors into account the total cost of one
TetR protein is 562 ATP. Following a similar calculation,
the cost of dCas9* PhlF is 5551 ATP.
RESULTS
Design and testing of a dCas9 variant with reduced toxicity
Transcription of a target reporter gene is blocked when a
dCas9-sgRNA complex binds to its promoter (Figure 1A).
Following the hypothesis that non-specific dCas9 binding
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Figure 1. Design and evaluation of a dCas9 – transcription factor fusion. (A) A schematic of targeted repression by dCas9-sgRNA complex bound to
the promoter region of a fluorescent reporter gene (RFP, red fluorescent protein). (B) A detailed schematic of the fused protein bound to a promoter is
shown. DBD is the DNA-binding domain that is fused to dCas9. GGN is the PAM site. R1335K is the mutation that reduces the PAM recognition ability
of dCas9. (C) The impact of changes to the fused protein and promoter on the response. The fold-repression is calculated as the ratio of uninduced to
induced (1 mM IPTG) cells (Methods). All constructs other than the first are based on dCas9* (R1335K). F and R represent the forward and reverse
orientations of the Zif268 operator. HNH refers to the deletion of this domain. L88 shows the impact of a longer linker. The size of the spacer between
the -35 and operator sequence is shown as SN, where N is the number of bp. Sequences and plasmid maps are shown in Supplementary Figure S12
and Supplementary Table S2. SrpR, HlyIIR and BM3RI are all TetR-family repressors that were tested as alternatives to PhlF. (D) The growth impact
of dCas9 and dCas9* PhlF is compared to the pSZ Backbone plasmid (Supplementary Figure S12) as a control. Protein expression is controlled using
the aTc-inducible system and the x-axis is shown in units of fluorescence for the pTet promoter, measured separately (Supplementary Figure S1). The
dashed line shows 2.5 ng/ml aTc, used in E for morphology studies. The arrows point to the inducer levels (0.7 ng/ml and 2.5 ng/ml) where the protein
concentrations are determined in Figure 1G. Media and growth conditions are provided in the Materials and Methods. (E) Microscopic images of E. coli
strains expressing PhlF, dCas9 or dCas9* PhlF variants and a control (Backbone) are shown, under identical conditions as used for the growth curves.
The scale bars are 5 m. The corresponding FSC-A/SSC-A distribution of each strain was measured by flow cytometry (Materials andMethods). (F) The
fold-repression of the construct (pSZ PhlF plasmid in Supplementary Figure S12 and the pPhlF S6 promoter from Supplementary Table S2) is shown as
a function of dCas9* PhlF expression. The sgRNA is under the control of the pTac promoter and all data are for 1 mM IPTG. The x-axis is the same as
described in D. The line shows a fit to a Hill equation. For B–F, the data are shown as the mean of three experiments performed on different days and the
error bars are the standard deviation. (G) A representative immunoblotting assay is shown for calculating the number of dCas9 per cell. The dashed lines
show the interpolation used to estimate concentrations. The calculation is described in the Methods and the numbers presented in the text are based on
three experiments performed on different days (Supplementary Figure S3).
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to DNA leads to its toxicity, we made a series of mutations
intended to disrupt binding. A schematic of these modifi-
cations is shown in Figure 1B. The RuvC* and HNH* do-
mains are mutated to disrupt the nuclease activity of Cas9
to create dCas9 (18). The promoter is based on the strong
constitutive promoter BBa J23101 (20), modified upstream
of the−10 position to contain a 20 bp sequence that is com-
plementary to the cognate sgRNA. The activity of this pro-
moter is measured using a transcriptional fusion to red flu-
orescent protein (rfp) and flow cytometry (Materials and
Methods). Binding to the PAM site (NGG) is disrupted
by making the R1335K mutation to dCas9 (53). Various
DNA-binding domains (DBD) are fused to the C-terminal
end of dCas9 and the corresponding operator is placed up-
stream of the −35 promoter region, separated by a spacer.
A linker is used to control the distance between the DBD
and dCas9.
A reporter system was developed to evaluate the impact
of these modifications on the ability for dCas9 to repress
the targeted promoter (Supplementary Figure S12). The
expression of the sgRNA and dCas9 are controlled using
IPTG- and aTc- inducible promoters, respectively. All of
these components are integrated into a single p15A plasmid
backbone. The fold-repression is measured as the fluores-
cence from the output promoter in the absence of sgRNA
inducer (0 mM IPTG), divided by the fluorescence when the
sgRNA is expressed (1 mM IPTG). When the R1335K mu-
tation is made (dCas9*), this completely abolishes repres-
sion as expected (Figure 1C).
We first tested the ability for a zinc finger protein (ZFP)
to recover nuclease activity. To this end, we built a variant of
dCas9* described previously, where Zif268TS3 is fused to the
C-terminal end of dCas9* via a 58 amino acid linker (53).
The corresponding 12 bp operator recognized by Zif268TS3
was then placed upstream of the promoter, separated from
the −35 position by a spacer (all promoter variants de-
scribed are provided in Supplementary Table S2). The ori-
entation of the operator (forward and reverse) was initially
tested with the forward yielding higher repression as pre-
viously observed (53). Thus, it was selected for all subse-
quent optimization. The deletion of the nuclease domain
(HNH) (56) and the increase in linker size to 88 amino
acids (L88) both improved repression (Figure 1C). Finally,
the length of the spacer was varied between 0 to 8 bp and
an optimum was identified at 6. Collectively, these changes
resulted in a ZFP fused dCas9 that can only achieve a max-
imum of 28-fold repression, roughly a third of the activity
of the unmodified variant.
TetR-family repressors were then evaluated in place of
the ZFP using the same dCas9* variant (88 amino acid
linker,HNH). Four repressors were tested (PhlF, BM3RI,
HlyIIR, and SrpR) and their corresponding operators (30,
20, 22, 30 bp, Supplementary Table S2) were inserted in
front of the promoter with the 6 bp spacer (8). Of these,
the PhlF fusion (dCas9* PhlF) recovered the most activity,
achieving 95% of the repression of dCas9 with an optimal
spacer length of 6 bp (Figure 1C).
The growth impact of dCas9 was then compared to
dCas9* PhlF at different levels of expression, controlled by
the addition of aTc. The activity of the pTet promoter is
used as a surrogate of dCas9 expression, measured in inde-
pendent experiments using a separate plasmid and red fluo-
rescent protein (Supplementary Figure S1). There is a clear
impact on growth, where cells expressing dCas9 rapidly de-
clines past an expression threshold (Figure 1D). In contrast,
there is only a slight defect at the highest expression lev-
els of dCas9* PhlF. The morphological impact on the cell
can be seen when aliquots are compared at the same level
of inducer (2.5 ng/ml aTc) (Figure 1E). The expression of
dCas9* leads to longer cells and larger side scatter (SSC-
A) (57), an effect described previously (28). However, when
expressing dCas9* PhlF or PhlF alone, the same level of
inducer leads to cell morphologies similar to wild-type E.
coli. Next, we tested whether the changes made to build
dCas9* PhlF simply disrupted its ability to act as a repres-
sor. Repression saturates at an expression level well before
any growth defect is observed (Figure 1F), thus indicating
the changes are not impacting performance.
Note that the use of promoter strengths to compare ex-
pression levels between dCas9 and dCas9* PhlF is, at best,
inexact as these genes will translate differently. Therefore,
we performed immunoblotting to quantify the size of the
pools of each protein that the cell can tolerate before a
growth impact is observed. Based on the growth experi-
ment, we chose 0.7 ng/ml aTc for dCas9 and 2.5 ng/ml
aTc for dCas9* PhlF as the maximum inducer levels be-
fore growth is impacted. (arrows in Figure 1D). The de-
tails of these experiments are presented in the Materials
andMethods. Briefly, a standard curve was generated using
commercially-available Cas9 of known concentration and
a Cas9-targeting monoclonal antibody (Figure 1G). Then,
wells are loaded with whole cell lysate from strains express-
ing dCas9 or dCas9* PhlF and the dCas9 number per well
is calculated from band intensity of that well by compar-
ing to the standard curve. The number of cells per ml were
also measured and used in the calculation (Supplementary
Figure S2). The average of three biological replicates, one
of which is shown in Figure 1G, determined that 9600 ±
800 molecules of dCas9* PhlF and 530 ± 40 molecules of
dCas9* are tolerated by a cell before growth and morphol-
ogy defects are observed (Supplementary Figure S3).
Design and characterization of sgRNA–promoter pairs as
NOT gates
A transcriptional NOT gate inverts the response of a pro-
moter (58). More complex circuits can be constructed by
connecting NOT gates to each other (e.g. toggle switch and
oscillator) or by converting to NOR gates through the ad-
dition of a second upstream input promoter (7,38,59,60).
Previously, we designed an architecture for NOT and NOR
gates based on sgRNAs using dCas9 (20). Here, we followed
this approach to build gates based on dCas9* PhlF, where
the input promoter driving sgRNA is an IPTG-inducible
pTac promoter (Figure 2A). The response of the output
promoter is measured using a transcriptional fusion to rfp.
These were combined to build a single plasmid using the
p15A backbone (Supplementary Figure S12). The plasmid
was transformed intoE. coli and cells were grown in inducer
until reaching steady-state (Materials and Methods).
The response function is characterized by comparing the
activity of the pTac promoter, measured separately, versus
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/20/11115/5115820 by M
IT Libraries user on 01 M
arch 2019
11120 Nucleic Acids Research, 2018, Vol. 46, No. 20
B
C
A
D
TetR
aTc
pTet dCas9*_PhlF
RFP
IPTG
pTac sgRNA9 p9LacI
NOT
p2
p8
p9
p3
p2 p8 p9
p8 p9 p3
pVan
pVan
pVan
pVan
Input
(pVan)
O
ut
pu
t
(p
2)
Figure 2. NOT gates based on dCas9* PhlF. (A) The schematic of the gate is shown. The input and output to the gate are pTac and p9. Part sequences
and plasmid maps are provided in Supplementary Figure S12 and Supplementary Table S3. (B) The response curves of dCas9-based NOT gates are shown
(Methods). The input is the activity of the pTac promoter as a function of IPTG concentration, measured separately (Supplementary Figure S1). The
concentration of dCas9* PhlF was maintained by adding 2.5 ng/ml aTc and 0.7 ng/ml for dCas9. (C) The response functions of 30 NOT gated based on
orthogonal pairs of sgRNAs and promoters. The sequences are provided in Supplementary Figure S11. The data were fit to Equation (1) and the resulting
parameters are provided in Supplementary Table S1. (D) Evaluation of cascades of different length. The detailed parts used in the genetic systems are
shown in Supplementary Figure S13. The color of the gate indicates the sgRNA:promoter pair used (blue: sgRNA2, light blue: sgRNA8, green: sgRNA9,
orange: sgRNA3). The input to the gate is the vanillic acid inducible promoter (pVan) and the x-axis is the activity of this promoter at different levels of
inducer, measured separately (Supplementary Figure S1). The color of the data corresponds to the last gate of the cascade. The fits to the data are the
responses predicted by combining the response functions of each layer of the cascade. The response functions of the individual gates and the predicted
propagation of the signal through the cascade are shown at the bottom (Methods). All of the data in this Figure are shown as the mean of three experiments
performed on different days and the error bars are the standard deviation.
the activity of the output promoter (Figure 2B and Materi-
als and Methods). The resulting data can be fit to the equa-
tion,
y = Ymin + (Ymax − Ymin) K
n
xn + Kn , (1)
where y is the output promoter activity (and Ymax/Ymin
are the maximum/minimum activities), x is the input pro-
moter activity, K is the threshold and n is the cooperativity.
Note that the values of the promoter activities are in arbi-
trary units of red fluorescence and not standardized units.
The response function from dCas9 is linear over the en-
tire range of input with n = 0.9, as observed previously
(Figure 2B). However, the response function resulting from
dCas9* PhlF has a clear S-shape with n = 1.6. The in-
creased cooperativity could be due to the multimerization
of PhlF, a mechanism supported by the loss in repression
observed by adding the PhlF inducer DAPG (Supplemen-
tary Figure S4).
A library ofNOT gates was then built based on a set of 30
orthogonal sgRNAs (20). The target sequence correspond-
ing to each was used to construct a promoter based on the
system shown in Figure 1B. The resulting NOT gates were
then characterized as before and fit to Equation (1). The
shapes of the curves are similar, but the maximum activ-
ity shifts as a result of the operator changes impacting pro-
moter strength (Figure 2C). On average, the gates exhibit a
47-fold dynamic range and the cooperativities span from 1.3
to 1.8. Because there are no cross reactions between gates,
these could be used as the basis for the construction of large
genetic circuits.
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Cascades were constructed to demonstrate the layering
of gates. First, the vanillic acid inducible system (pVan) was
selected to serve as the input because it was observed to gen-
erate the largest dynamic range (341-fold) (Supplementary
Figure S5). This was used as the input for a series of cas-
cades based on 1 to 4 sgRNAs (Figure 2D and Supplemen-
tary Figure S6). The predicted response (solid lines) of each
cascade was calculated by mathematically combining the
response functions of the individually-measured gates. For
the first three layers, the measured response closely matches
that predicted. However, the addition of the fourth layer
leads to a significant deviation from the predicted response.
When dCas9* PhlF was expressed at lower levels, the mea-
sured responses deviated from the predicted responses even
in the first two layers (Supplementary Figure S7).
Sharing of the dCas9* PhlF pool by multiple sgRNAs
Genetic circuits with more than one gate require the simul-
taneous expression of multiple sgRNAs within the cell that
need to compete with the same pool of dCas9 molecules.
The sharing impacts the dynamics of each component in the
system and this can have unintended consequences for the
overall behavior of the circuit (31). Therefore, it is impor-
tant to quantify the titration that occurs as more sgRNAs
are simultaneously expressed.
First, we characterized the impact of resource sharing be-
tween two sgRNAs (Figure 3A). The pBetI promoter was
used to generate a constitutive level of sgRNA9, which re-
presses the p9 promoter. The vanillic acid inducible pro-
moter (pVan) then drives a second sgRNA10. As vanillic
acid is added and the second sgRNA is transcribed at higher
levels, there is almost no impact on the ability of the first
to repress its promoter. This is true even when sgRNA10 is
expressed at the level required for the full repression of its
cognate p10 promoter. Therefore, both sgRNAs can be fully
expressed and independently repress two promoters with-
out incurring significant effects due to resource sharing.
It is expected that as more sgRNAs are added to the
system, at some point there would be a decline in their
ability to function as dCas9* PhlF is titrated. To quan-
tify this transition, we developed a mathematical model
inspired closely by the work of Del Vecchio and co-
workers (BioRxiv: https://www.biorxiv.org/content/early/
2018/02/14/266015). The equations corresponding to when
two sgRNAs are expressed are described below and this is
expanded to a system of i sgRNAs in the Supplementary
Note. The pool of total dCas9 CTOT is assumed to be con-
stant. It can be described as the algebraic sum of free dCas9
CF and the concentrations of dCas9 bound to the first and
second sgRNAs (s1 and s2),
CTOT = CF + Cs1 + Cs2 (2)
The dynamics of the unbound sgRNAs s1 and s2 are cap-
tured by the differential equations
ds1
dt
= α1 − δss1 − k1CFs1 + k−1Cs1 and (3)
ds2
dt
= α2 − δss2 − k1CFs2 + k−1Cs2 and (4)
where α1 and α2 are the transcription rates of the first and
second sgRNAs. δs is degradation rates, and assumed to be
the same for different sgRNAs. Similarly, the on- and off-
rates of sgRNAs to dCas9 (k1 and k-1) are assumed to be
sequence independent. There are two additional differential
equations for the formation of sgRNA::dCas9 complexes:
dCs1
dt
= k1CF s1 − k−1Cs1 and (5)
dCs2
dt
= k1CF s2 − k−1Cs2 (6)
Finally, the concentration of free dCas9 is given by
dCF
dt
= −k1CF s1 − k1CFs2 + k−1Cs1 + k−1Cs2. (7)
At steady-state, Equations (2–7) reduce to
s1 = α1
δs
and (8)
Cs1 = K1s1CTOT1 + K1s1 + K1s2 , (9)
where K1 is the association equilibrium constant of sgRNA
to dCas9. This captures how increasing the concentration of
the second sgRNA impacts the concentration of complexes
with the first. By substituting sgRNA concentration from
Equation (8), we can simplify Equation (9) to
Cs1 = α1CTOT
β + α1 + α2 , (10)
where β = δsK1 .
Considering a Shea–Acker’s model of a repressor binding
to a promoter (related in form to Equation 1), the impact on
transcription would be:
G
Gss
= 1 + Cs1
n
Kn
, (11)
where G/Gss is the fold-repression, K is the dissociation
equilibrium constant for dCas9::sgRNAbinding to the pro-
moter, and n is the cooperativity. Combining Equations (10)
and (11) shows how the expression of a second sgRNA
impact the repression of promoter responsive to the first
sgRNA.
Similarly, concentration of the first sgRNA::dCas9 com-
plex can be derived when multiple competing sgRNAs are
co-expressed and sharing the dCas9 pool (Supplementary
note):
Cs1 = α1CTOT
β + α1 + NαX (12)
where N is the number of additional co-expressed sgRNAs
and αx is the transcription rate of these competing sgRNAs.
The concentration for each of these competing sgRNAs is
assumed to be equal. The fold-repression is calculated by
substituting Cs1 from Equation (12) into Equation (11).
To parameterize the model, we measured how the re-
sponse of a sgRNA declines as more competing sgRNAs
are added to the system. The response of a vanillic acid-
driven NOT gate based on sgRNA9 was measured; alone,
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Figure 3. The impact of simultaneous expression of multiple sgRNAs. (A) Expression of sgRNA9 was fully induced (10 mM choline, activating pBetI) to
measure fold-repression of promoter p9 (orange), while the expression level of sgRNA10 (green) was induced by adding different levels of vanillic acid. The
activity of the pVan promoter was measured separately as a function of vanillic acid concentration (Supplementary Figure S1). The detailed parts used
in the genetic systems are shown in Supplementary Figure S13. Solid lines are model prediction results. (B) The impact of expressing multiple sgRNAs
simultaneously. The repression fold change of promoter p9 was measured with or without the addition 100 M vanillic acid. The constructs containing
different numbers of sgRNAs are shown to the right. The sequences corresponding to the promoters and terminators are provided in Supplementary
Table S3. The sgRNAs are labeled sgN where N corresponds to the sequences in Supplementary Figure S11. The horizontal line marks 10-fold repression,
roughly the minimum required for useful NOT gates. For dCas9* PhlF, the fit parameters for Equations (11) and (12) are β = 3.0 × 10−11 Ms−1, α1 = 7.6
× 10−12 Ms−1, αx = 2.3 × 10−11 Ms−1, K = 1.7 × 10−8 M, n = 0.9. For dCas9, the fit parameters are: β = 3.0 × 10−11 Ms−1, α1 = 7.6 × 10−12 Ms−1, αx
= 2.3 × 10−11 Ms−1, K = 2.9 × 10−9 M, n = 1.1, In both parts, the data are shown as the mean of three experiments performed on different days and the
error bars are the standard deviation.
it generates 58-fold repression (Figure 3B). Then, a series of
constructs were designed to express increasing numbers of
sgRNAs, from 1 to 16. Each expression unit consists of the
same pCon constitutive promoter, a different sgRNA (but
conserving the tracrRNA sequence), and different strong
terminators (part sequences in Supplementary Table S3).
The constructs involve the repetition of these units within a
single construct. While effort was made to minimize repet-
itive DNA, sufficient regions of sequence similarity remain
so special cloning procedures were used and construct sta-
bility confirmed by digestion (Methods and Supplementary
Figure S8).
Our goal was to evaluate a maximum number of sgR-
NAs that can be used together. Therefore, we tuned the sys-
tem to minimize the expression level of each sgRNA to the
point where they are as low as possible but still could min-
imally function as a NOT gate. In accordance with this ap-
proach, the constitutive promoter (pCon) was selected such
that each sgRNA yields ∼10-fold repression when mea-
sured in the context of the N16 construct (Supplementary
Figure S9). In essence, this maximizes the number of sgR-
NAs that can be used simultaneously, thus representing an
upper limit. The growth impact of expressing sgRNAs was
also measured and only a slight decrease in the growth of E.
coli cell was observed as more sgRNAs were simultaneously
expressed (Supplementary Figure S10).
The impact on the sgRNA9 gate was measured as a
function of the number of additional sgRNAs co-expressed
(Figure 3B). The additional sgRNAs do not bind to any
DNA sequences in the system because their cognate pro-
moters are not included. This response was compared for
both dCas9 and dCas9* PhlF expressed to the maximal
level prior to observing a growth defect (0.7 and 2.5 ng/ml
aTc, respectively). In both cases, there is a significant decline
in repression evenwith the first few additional sgRNAs. The
slope is steeper for dCas9 and the response falls below 10-
fold after seven more sgRNAs are co-expressed, while for
dCas9* PhlF this increases to 14 sgRNAs.
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DISCUSSION
The original uses intended for Cas9 and dCas9 have dif-
ferent constraints than those required for genetic circuits.
Genome editing and knockdown experiments only require
transient and low levels of expression for activity. These ap-
plications benefit from the capability of sgRNA to be de-
signed to target essentially any region of the genome and
this programmability could be very useful for building out
sets of orthogonal regulators for genetic circuits. However,
integrating a circuit into an application is more compli-
cated, for example to produce a chemical product in a fer-
menter or integrate information in the human gut (61–65).
For these purposes, a circuit cannot reduce growth or re-
quire significant cellular resources or energy to function.
In this manuscript, we have solved one of these problems,
where the growth impact of dCas9 is greatly reduced by in-
creasing the required DNA sequence to which it binds by
swapping a 3 bp PAMsite for a 30 bp PhlF operator. This al-
lows the expression of dCas9* PhlF to be increased to∼104
copies per cell, which is just about as high as one can expect
to push the expression of a large protein in E. coli (66).
Repetitive sequences shared between gates is another
challenge that must be solved before large sgRNA circuits
can be built based on dCas9* PhlF. The shared sequences
can lead to genetic instability due to homologous recom-
bination (67,68). All of the sgRNA-based gates share the
identical 83 bp tracrRNA sequences, and the output pro-
moters share the identical 30 bp PhlF operator (Supplemen-
tary Figure S11). In addition, converting the NOT gates to
NOR gates requires either duplicating the sgRNA or using
a ribozyme to cleave 5′-UTR generated by two upstream
promoters in series (7,20,21). Both of these approaches
lead to longer regions of repeated DNA. Stabilizing circuits
would require sequence diversification and the creation of
part libraries (e.g. of ribozymes) with diverse sequences, ap-
proaches that have been applied previously (69,70).
However, before undertaking this effort, it is important
to consider whether the concept makes sense. The pool of
dCas9* PhlF would need to be maintained at a constant
∼104 molecules irrespective of the number of active gates.
Our experimental data and model show that this can sup-
port about 15 sgRNA-based gates (Supplementary note).
This is about on par with the number of available protein-
based gates and is a harsh limitation to the huge number of
potential gates considering sgRNA programmability alone
(estimated to be ∼107 sgRNA–promoter pairs) (20). The
retroactivity due to having to share the dCas9* PhlF re-
source also changes as each additional sgRNAs is added to
the system. When designing circuits, a mathematical model
would have to be used to mitigate this complexity. Thus, the
benefit of sgRNA-based gates, evenwhen the dCas9 toxicity
is solved, is not a dramatic increase in circuit size. However,
there may be other benefits in some cases.
One such scenario may be in eukaryotes where using
dCas9-based gates have an advantage (6,21,71). The lack
of translation at the gate level means that that circuit func-
tion can be entirely localized to the nucleus (once a dCas9
pool has been imported), thus avoiding the problem with
protein-based gates, where the regulator mRNA must be
exported from the nucleus and the regulator protein im-
ported. Another may be for organisms where for which the
circuit needs to be carried at low copy and the design of
high-expression promoters remains elusive (63).
It is not true that sgRNA gates require less cellular re-
sources because they do not require translation to func-
tion. While each gate only requires a new sgRNA to be
transcribed, for it to be functional it needs a dCas9* PhlF
to form a complex that represses the output promoter.
The binding of sgRNA to dCas9 is very tight (Kd = 10
pM) (50) and dCas9 binds tightly to DNA (Kd = 1 nM)
(42,72,73), requiring DNA replication machinery for re-
moval during division (39). Therefore, it is likely that recy-
cling of the pool will be low (reuse of dCas9 after dissoci-
ating from a previous sgRNA). This makes the cost of each
dCas9* PhlF:sgRNA ‘repressor’ high when compared to a
protein-based repressor (e.g. TetR). Putting it in terms of
ATP consumption, an estimation is that the former requires
∼5000 ATP/repressor and the latter ∼500 ATP/repressor
(Methods).
The sharing of a resource is a common feature of cells,
including natural regulatory networks (74,75). One example
are sigma factors, turned on in response to different cellular
needs, that all must share core RNA polymerase to initiate
transcription from a promoter (76). If multiple sigma fac-
tors were co-expressed, this would draw down the core re-
source. It has been shown that B. subtilis has an innovative
solution: each sigma factor is expressed as an independent
pulse and the pulsing time is changed with respect to need,
as opposed to the expression level (77). In the natural net-
work, this is achieved with feedback loops of a complexity
still difficult to achieve in engineered systems. Our results
point to the difficulty of using a genetic circuit paradigm
that requires a shared (and expensive) non-recyclable re-
source in bacteria. This work highlights the need to develop
theoretical and experimental frameworks to quantify the
cellular impact of introducing systems into cells, prior to
performing experiments, in order to rationally guide design
decisions.
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